BMRN - Bernstein upgrades BioMarin to market perform citing valuation
2023-10-23 16:05:17 ET
More on BioMarin Pharmaceutical
- BioMarin: Growth Drivers Remain Intact
- BioMarin: Q2 2023 Confirmed My Bullish View
- Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Call Transcript
- FDA approves use of BioMarin drug Voxzogo in children under 5
- BioMarin a market perform at Raymond James due to growth concerns
For further details see:
Bernstein upgrades BioMarin to market perform, citing valuation